Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 8 August are set out below…
Pearce IP BioBlast® for the week ending 8 August 2025
read more
Pearce IP BioBlast® for the week ending 1 August 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 1 August are set out below…
Pearce IP BioBlast® for the week ending 25 July 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 25 July are set out below…
Pearce IP BioBlast® for the week ending 18 July 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 18 July are set out below…
Pearce IP BioBlast® for the week ending 11 July 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 11 July are set out below…
Pearce IP BioBlast® for the week ending 4 July 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 4 July are set out below…
Extended Release, Expeditious Rejection: Federal Court Invalidates Sun Pharma’s Aripiprazole PTE
On 5 February 2025, Justice Downes of the Federal Court of Australia delivered her decision in the dispute between Otsuka Japan and its licensees (Lundbeck A/S and Australia and Otsuka Australia) (collectively…
Pearce IP BioBlast® for the week ending 27 June 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 27 June are set out below…
Pearce IP BioBlast® for the week ending 20 June 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 20 June are set out below…
Pearce IP BioBlast® for the week ending 13 June 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 13 June are set out below…
Pearce IP BioBlast® for the week ending 6 June 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 6 June are set out below…
Pearce IP BioBlast® for the fortnight ending 30 May 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 30 May are set out below…
Scanning for Justice: Hytera’s Radio Technology Appeal Falls on Deaf Ears
The Full Court of the Federal Court has delivered judgment in the proceedings between Motorola Solutions Inc (Motorola) and Hytera Communications Corporation Ltd (Hytera), in their ongoing…
Pearce IP BioBlast® for the week ending 16 May 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 16 May are set out below…
Pearce IP BioBlast® for the week ending 9 May 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 9 May are set out below…
Pearce IP BioBlast® for the week ending 2 May 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 2 May are set out below…